Non-24 is a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind.
The company has launched HETLIOZSolutions to support and facilitate the treatment of totally blind people living with Non-24.
It will provide patients the information about Non-24 and HETLIOZ, insurance support, overview of financial assistance programs, and pharmacy access.
Vanda president and chief executive officer Mihael Polymeropoulos said the availability of HETLIOZ marks a major milestone for totally blind people who have been without an approved, safe and effective treatment for Non-24.
"We are also excited to bring a broad range of services to patients through HETLIOZSolutions," Polymeropoulos said.
Hetlioz, which was approved by the US Food and Drug Administration (FDA) in January 2014, is available through specialty pharmacies in the US.
Image: The FDA approved Hetlioz is indicated for the treatment of Non-24. Photo: courtesy of posterize